Table 5 Thirty-day Occurrence of net adverse clinic events after matching
Short-time group (n = 432) | Long-time group (n = 432) | Hazard Ratio (95% CI) | P value | |
|---|---|---|---|---|
MACCEs (n,%) | 13 (3.0%) | 12 (2.8%) | 0.49–2.41 | 1.00 |
Death (n,%) | 3 (0.69%) | 3 (0.69%) | 0.20–4.92 | 1.00 |
Myocardial infarction (n,%) | 8 (1.9%) | 7 (1.6%) | 0.41–3.20 | 1.00 |
STEMI | 2 (0.5%) | 3 (0.7%) | 0.11–3.97 | 1.00 |
NSTEMI | 6 (1.4%) | 4 (0.9%) | 0.43–5.28 | 0.75 |
Definite/ Probable Stent thrombosis (n,%) | 3 (0.7%) | 5 (1.2%) | 0.17–3.37 | 0.73 |
Stroke (n,%) | 5 (1.2%) | 5 (1.2%) | 0.29–3.43 | 1.00 |
Bleeding and access-related complications (n,%) | 24 (5.6%) | 26 (6.0%) | 0.52–1.63 | 0.88 |
Major Bleeding | 7 (1.6%) | 8 (1.8%) | 0.29–2.07 | 1.00 |
Arteriovenous fistula | 2 (0.46%) | 1 (0.23%) | 0.18–21.9 | 1.00 |
False aneurysm | 5 (1.2%) | 4 (0.9%) | 0.33–4.70 | 1.00 |
Hematoma | 11 (2.5%) | 12 (2.1%) | 0.40–2.10 | 1.00 |
Net adverse clinic events (n,%) | 37 (8.6%) | 38 (8.8%) | 0.60–1.56 | 1.00 |